Abstract
The Center for Breakthrough Medicines (CBM), a cell and gene therapy contract services firm, plans to expand research and manufacturing with an investment from SK . CBM was established in 2019 by the Discovery Labs after the latter acquired a GlaxoSmithKline R&D center in King of Prussia, Pennsylvania. CBM says it will hire 2,000 people over the next 4 years. SK, a South Korean company with investments in life sciences, energy, and other industries, says it will partner with CBM in providing cell and gene therapy services.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
